ArticleMolecules (Basel, Switzerland)2019
Synthesis of Hydrazone Derivatives of 4-[4-Formyl-3-(2-oxochromen-3-yl)pyrazol-1-yl]benzoic acid as Potent Growth Inhibitors of Antibiotic-resistant
Article in Molecules (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 27 citations in OpenAlex.
- The Application of the Pyrazole Structure in the Structural Modification of Natural Products.Mini reviews in medicinal chemistry · 2025Review
- Pyrazole: an emerging privileged scaffold in drug discovery.Future medicinal chemistry · 2023Review
- An interpretable machine learning approach to identify mechanism of action of antibiotics.Scientific reports · 2022Article
- Antibacterial pyrazoles: tackling resistant bacteria.Future medicinal chemistry · 2022Review
- Novel pyrazoles as potent growth inhibitors of staphylococci, enterococci andFuture medicinal chemistry · 2022Article
- Design, synthesis, and antibacterial activity ofRSC medicinal chemistry · 2021Article
- Synthesis of Chimeric Thiazolo-Nootkatone Derivatives as Potent Antimicrobial Agents.ChemMedChem · 2021Article
- Synthesis of 3,5-Bis(trifluoromethyl)phenyl-Substituted Pyrazole Derivatives as Potent Growth Inhibitors of Drug-Resistant Bacteria.Molecules (Basel, Switzerland) · 2021Article
- Antimelanoma activities of chimeric thiazole-androstenone derivatives.Royal Society open science · 2021Article
- 4-4-(Anilinomethyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-ylbenzoic acid derivatives as potent anti-gram-positive bacterial agents.European journal of medicinal chemistry · 2021Article
- Benign Synthesis of Fused-thiazoles with Enone-based Natural Products and Drugs for Lead Discovery.New journal of chemistry = Nouveau journal de chimie · 2021Article
- Synthesis of 4,4'-(4-Formyl-1Antibiotics (Basel, Switzerland) · 2020Article
- Synthesis and Antimicrobial Studies of Coumarin-Substituted Pyrazole Derivatives as Potent Anti-Molecules (Basel, Switzerland) · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Microbial resistance to drugs is an unresolved global concern, which is present in every country. Developing new antibiotics is one of the guidelines of the Centers for Disease Control and Preventions (CDC) to combat bacterial resistance to drugs. Based on our lead molecules, we report the synthesis and antimicrobial studies of 27 new pyrazole derivatives. These new coumarin-pyrazole-hydrazone hybrids are readily synthesized from commercially available starting materials and reagents using benign reaction conditions. All the synthesized molecules were tested against 14 Gram-positive and Gram-negative bacterial strains. Several of these molecules have been found to be potent growth inhibitors of several strains of these tested bacteria with minimum inhibitory concentrations as low as 1.56 μg/mL. Furthermore, active molecules are non-toxic in in vitro and in vivo toxicity studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.